Classes
DEA Class; OTC
Common Brand Names; Sudafed, Nexafed, Zephrex-D
- Decongestants, Systemic
Description
Oral sympathomimetic decongestant agent
Primarily used in adults and pediatric patients 4 years and older to temporarily relieve nasal congestion due to the common cold, allergic rhinitis, or other upper respiratory conditions
Due to potential for diversion as a substrate for the illegal synthesis of amphetamine and methamphetamine, sales of pseudoephedrine-containing products are regulated by the Combat Methamphetamine Epidemic Act
Indications
Contraindications
Hypersensitivity
Severe hypertension, severe CAD
Within 14 days of MAO inhibitor therapy
Adverse Effects
- Tremor
- Restlessness
- Insomnia
- Nausea
- Vomiting
- Nervousness
- Hypertension
- Atrial fibrillation
- Myocardial infarction
- Ventricular premature beats
- Ischemic colitis
Warnings
Use caution in mild to moderate hypertension, cardiac disease, hyperthyroidism, hyperglycemia, BPH, DM, renal impairment, seizure disorder, thyroid dysfunction, glaucoma, lactation
Elderly may be more sensitive to side effects
When used for self-medication, see health-care provider if symptoms do not improve within 7 days or are accompanied by fever
Some products may contain sodium
Some dosage forms may contain sodium benzoate/benzoic acid; large amounts have been associated with a potentially fatal toxicity (gasping syndrome) in neonates
Many combo formulations are switching to phenylephrine due to restrictions arising from easy conversion to methamphetamine (the Combat Methamphetamine Epidemic Act of 2005 bans OTC sales of cold medicines that contain ingredients, such as pseudoephedrine, commonly used to make methamphetamine)
Pregnancy and Lactation
Avoid, during first trimester; may be associated with possible risk of gastroschisis, small intestinal atresia, and hemifacial microsomia due to pseudoephedrine’s vasoconstrictive effects; magnitude of risk unknown
Excreted in breast milk; irritability reported in nursing infants (limited data); milk production may be decreased in some women
Maximum Dosage
240 mg/day PO.
240 mg/day PO.
240 mg/day PO.
12 years: 240 mg/day PO.
6 to 11 years: 120 mg/day PO.
4 to 5 years: 60 mg/day PO.
2 to 3 years: Safety and efficacy have not been established for non-prescription (OTC) use. Consult doctor prior to use. Previously recommended maximum dose was 60 mg/day PO.
Less than 2 years: Safety and efficacy have not been established.
Safety and efficacy have not been established.
How supplied
Pseudoephedrine hydrochloride
tablet, immediate-release
- 30mg
- 60mg
tablet, extended-release
- 120mg
- 240mg
tablet, IMPEDE technology (Nexafed)
- 30mg
- IMPEDE technology utilizes an advanced polymer matrix to limit extraction of pseudoephedrine from tablets and deter methamphetamine manufacturing
tablet, TAREX technology (Zephrex-D)
- 30mg
- TAREX technology utilizes an advanced polymer matrix to limit extraction of pseudoephedrine from tablets and deter methamphetamine manufacturing
syrup
- 3mg/mL